Aethlon Medical, Inc.(OTCMKTS:AEMD) has seen a spectacular rise up in recent trading after the Company announced on October 14 the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany.
Obviously this is massive news considering that Ebola is a deadly virus that is currently sweeping across West Africa with over 10,000 confirmed cases and almost half as many deaths. The outbreak which is easily the biggest Ebola outbreak in history continues to spread like wild fire with new cases now being reported in Texas, USA.
The recent news by AEMD has sent the stock skyward on massive volume and many investors suggest this one is just getting started with more news on the Ebola treatment expected to be forthcoming from the Company.
To Find out the inside Scoop on AEMD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders. The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.
AEMD has a broad product pipeline that includes the Aethlon ADAPT™ System, The Aethlon Hemopurifier®, HER2osome™ ELLSA™ Exosome Assay and DARPA Sepsis Program.
The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and numerous bioterror and pandemic threats. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both HCV and HIV infected individuals without the administration of antiviral drugs. The device is currently the subject of a human clinical study in India to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy. An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with The Food and Drug Administration (FDA).
In vitro studies have also documented that the Hemopurifier® captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. We have expanded our exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration is studying the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.
On October 14 AEMD announced the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.
In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating ebola to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response. The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.
Conclusion: AEMD has seen a recent fast rise in price and massive increase in trading volume after the Company announced they were treating an Ebola patient with their Hemopurifier® therapy. Unlike a one day wonder that would have dropped by now AEMD continues to hold its gains suggesting this one has much more coming.
Currently trading at a $62 million market valuation the recent developments are enough to keep AEMD in the spotlight for a while as Ebola continues to dominate both local and international headlines.
As AEMD forms a base here at the $0.025 level smart investors have their eye on recent high of $0.307 once AEMD surpasses that, this one is wide open with nothing but green sky’s ahead!
We have a Monster Pick Coming. Subscribe Right Now!
Disclosure: we hold no position in AEMD either long or short and we have not been compensated for this article.